Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTs

NCT04353466 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Gaucher Disease, Type 1

Interventions

PROCEDURE: quantitative chemical shift imaging (QCSI)
DRUG: Elelyso

Sponsor

Shaare Zedek Medical Center

Collaborators

[object Object]